Recently launched drug-coated balloons for peripheral artery disease were awarded Medicare new-technology add-on payments by CMS for the coming fiscal year, building on prior positive reimbursement news for the devices.
Drug-Coated Balloons Net Medicare Inpatient Bonus Payments
The positive hospital inpatient reimbursement decision for recently launched Medtronic and CR Bard peripheral artery devices follows prior positive policy rulings in the outpatient setting. Meanwhile, CMS rejected Boston Scientific's new-technology add-on application for the Watchman stroke device, but the agency did establish a pricier payment category for the new procedure.
More from Policy & Regulation
More from Medtech Insight
• By
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.
• By
Beyond the US market, Monogram is actively pursuing regulatory approvals abroad, with India as a key target. The company has partnered with Shalby Hospitals, one of India’s largest orthopedic hospital networks, to conduct clinical trials and accelerate regulatory clearance in the region.
